Skip to content

PREdelivery Placental Biomarkers- Pregnancy and Delivery Outcome

The PREPPeD Study: PREdelivery Placental Biomarkers- Pregnancy and Delivery Outcome

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03100084
Acronym
PREPPeD
Enrollment
1000
Registered
2017-04-04
Start date
2016-09-15
Completion date
2022-09-01
Last updated
2020-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Placental Insufficiency, Pregnancy Complications

Keywords

Preeclampsia, Diabetes in Pregnancy, Fetal Growth Restriction, Reduced Fetal Movements

Brief summary

The PREPPeD study proposes that predelivery placenta-derived maternal circulating biomarkers reflect placental health, capacity and ageing, and can help predict onset and complications of delivery both in complicated pregnancies as well as in clinically uncomplicated term/post-term pregnancies.

Detailed description

The main aim of the PREPPeD study is to explore whether placental health, evaluated by maternal blood biomarkers in late pregnancy, correlates with delivery outcomes in both healthy and complicated pregnancies.

Interventions

OTHERBlood sampling

Maternal blood sampling

Sponsors

Norwegian SIDS and Stillbirth Society
CollaboratorOTHER
Extrastiftelsen
CollaboratorOTHER
Oslo University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
Yes

Inclusion criteria

* All pregnant women scheduled to deliver at the Department of Obstetrics at OUH who qualify for the study groups as specified in the Groups and Intervention section.

Exclusion criteria

* Women who do not understand Norwegian or English * Communicable disease * Younger than 18 years of age * Legally incompetent * Fetal malformations

Design outcomes

Primary

MeasureTime frameDescription
Rate of acute cesarean section (due to suspected fetal distress)Data assessed throughout study period of 140 months
Meconium aspiration syndromeDiagnosis within 28 days postpartum; data assessed throughout study period of 140 months
Neonatal hypoxic-ischemic encephalopathyDiagnosis within 28 days postpartum; data assessed throughout study period of 140 months
Therapeutic hypothermia of the neonateWithin 3 days postpartum; data assessed throughout study period of 140 months
Fetal acidaemiaUmbilical cord gas/lactate are sampled directly post partum within 45 min; data assessed throughout study period of 140 monthsIn neonates delivered by cesarean section (CS) without labour (defined as absence of regular uterine contractions): Umbilical artery blood (transporting blood from the fetus to the placenta) pH\<7.13 and arterial BD \>10.0 In neonates from labored delivery (regardless of subsequent delivery method, vaginal or CS): Umbilical artery blood pH\<7.05 and arterial BD\>14; OR Umbilical artery blood (or venous if arterial blood not available) lactate above Reference level for respective gestational age according to publication by Wiberg N et al ,BJOG 2008 (doi: 10.1111/j.1471-0528.2008.01707.x.)
Newborn low Apgar scoreApgar score is assessed directly post partum within 10 minutes; data assessed throughout study period of 140 months\<4 at 1 minute OR \<7 at 5 minutes
Newborn asphyxiaDirectly post partum within 10 and 45 minutes respectively; data assessed throughout study period of 140 monthsCombination of outcomes 1 and 2
Rate of intrauterine fetal demise/intra-/postpartum fetal deathDiagnosis within 28 days postpartum; data assessed throughout study period of 140 months
Neonatal intubation/mechanical ventilation>6 hoursWithin 28 days postpartum; data assessed throughout study period of 140 months

Secondary

MeasureTime frame
Pathological placenta histology findingsData assessed throughout study period of 140 months
Abnormal intrapartum CTG patternsIntrapartum CTG; data assessed throughout study period of 140 months
Rates of operative vaginal deliveries (forceps/vacuum/combined; due to suspected fetal distress)Data assessed throughout study period of 140 months

Countries

Norway

Contacts

Primary ContactMeryam Sugulle, PhD, MD
uxsume@ous-hf.no+4722119800
Backup ContactAnne Cathrine Staff, PhD, MD
uxnnaf@ous-hf.no+4722119800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026